Medication info
Polmin Empagliflozin & Metformin Controlled Release Tablet 5/1000 mg

Polmin Empagliflozin & Metformin Controlled Release Tablet 5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Green Cross Corporation
Appearance
Gray, oval-shaped, convex, controlled-release film-coated tablet
Packaging
30 tablets per bottle
Approval status
Active

MFDS item code 202501714 · Approved 2025.07.09 · Insurance code 643606870

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antihyperglycemic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and 2000 mg as extended-release metformin hydrochloride. This drug should be taken once daily with a meal in the evening to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this drug 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this drug 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets at the same time once daily. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs, such as insulin, the initial recommended total daily dose when taking this drug is empagliflozin 10 mg and the patient's existing metformin dose. If the patient tolerates empagliflozin 10 mg well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant therapy with empagliflozin and metformin to this drug should receive their existing doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. When this drug is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this drug should be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Green Cross Corporation

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Blood sugar control issues in adult patients with type 2 diabetes; cardiovascular disease
View approved original text

This medication is used as an adjunct to improve blood sugar control in adult patients with type 2 diabetes when used in conjunction with diet and exercise. It can be particularly effective in cases where blood sugar is not adequately controlled with either empagliflozin or metformin alone. Furthermore, patients with type 2 diabetes who have established cardiovascular disease should refer to specialist advice regarding the risk of cardiovascular events. This drug plays an important role in blood sugar management and treatment of type 2 diabetes.

How to take

Adult dose

In antihyperglycemic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and 2000 mg as extended-release metformin hydrochloride. This drug should be taken once daily with a meal in the evening to reduce gastrointestinal adverse reactions caused by metformin. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this drug 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. Patients taking this drug 5/1000 mg extended-release tablet or 12.5/1000 mg extended-release tablet should take 2 tablets at the same time once daily. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other drugs, such as insulin, the initial recommended total daily dose when taking this drug is empagliflozin 10 mg and the patient's existing metformin dose. If the patient tolerates empagliflozin 10 mg well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant therapy with empagliflozin and metformin to this drug should receive their existing doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. When this drug is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to below 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to below 45 ml/min/1.73m2, this drug should be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication can rarely cause a serious condition known as lactic acidosis, and patients should be well aware of these symptoms. Lactic acidosis can occur when there is a high concentration of lactate in the blood, leading to acidification that can become life-threatening. Caution is necessary when using this drug with other diabetes medications, as there is a risk of hypoglycemia. Patients with moderate or severe renal impairment or renal failure should not take this medication. It should also not be administered in situations where renal function may rapidly decline. This medication is not used in patients with type 1 diabetes or diabetic ketoacidosis, nor in patients with acute or unstable heart failure. Particularly before and after tests using iodinated contrast agents, administration of this medication should be stopped and restarted only after renal function has returned to normal. It should also be discontinued for a certain period before and after surgery, and resumed only after physical stability is achieved. It is advisable not to administer this medication to patients with liver dysfunction, severe pulmonary dysfunction, excessive alcohol consumption, dehydration, diarrhea, or vomiting that could affect overall health. It is not recommended for women who are pregnant or may become pregnant, or for those who are breastfeeding; if breastfeeding, mothers should discontinue nursing. Elderly patients or those with reduced renal function should have their dosage adjusted and undergo regular renal function monitoring. During treatment, patients should be watchful for symptoms of hypoglycemia, especially if used in conjunction with insulin or sulfonylureas, as the risk of hypoglycemia can be increased. Urinary tract infections or genital infections may occur, so any symptoms of infection should be immediately discussed with healthcare providers. This medication may cause fluid loss, hence adequate hydration is necessary to avoid dehydration. Long-term use may lead to vitamin B12 deficiency, so it’s advisable to monitor blood vitamin B12 levels periodically. Alcohol consumption may increase the risk of side effects from this medication, so excessive drinking should be avoided while on treatment. This medication should not be broken or chewed, but swallowed whole; the tablet shell may pass in stool, which is a normal occurrence. While using this medication, regular monitoring of blood glucose and renal function is required, and any unusual symptoms should be promptly discussed with a physician.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • lactic acidosis
  • decreased fluid volume
Show 132 more
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • perineal necrosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • pancreatic adenocarcinoma
  • hypoglycemic episodes
  • decreased appetite
  • obesity
  • dyslipidemia
  • sebaceous cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • retinal detachment with holes
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • age-related dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina pectoris
  • palpitations
  • Prinzmetal's angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • otalgia
  • orthostatic dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid mass
  • vulvar pruritus
  • genital pruritus
  • hyperglycemia
  • dyslipidemia
  • thoracic discomfort
  • chest pain
  • weakness
  • weight loss
  • cervical inflammation
  • urinary stones
  • fever
  • facial swelling
  • chills
  • strange sensation
  • edema
  • pain
  • pain at puncture site
  • vascular stent stenosis
  • vascular stent thrombosis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, ideally at a temperature between 1 and 30 degrees Celsius. Proper storage will maintain the drug's effectiveness and ensure safe usage.

Appearance and packaging

Appearance

Gray, oval-shaped, convex, controlled-release film-coated tablet

Package unit

30 tablets per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.